Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)

NCT06919354 is registered in ClinicalTrials.gov with GentiBio, Inc as lead sponsor.

NCT NCT06919354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06919354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)
Lead sponsor
GentiBio, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
September 3, 2025
Completion date
February 29, 2028
Enrollment
16 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes (t1d), type 1 diabetes mellitus